Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells

Virus Research

Volumn 168, Issue 1-2, 2012, Pages 33-40

  Ye, Li ^a,b   Li, Jieliang ^b   Zhang, Ting ^c   Wang, Xu ^b   Wang, Yizhong ^b   Zhou, Yu ^b   Liu, Jinping ^d   Parekh, Hemant K ^b   Ho, Wenzhe ^a,b  

^a WUHAN UNIVERSITY   (China)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FUDAN UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

HCV recurrence; Immunosuppressant; Liver transplantation; Mycophenolate mofetil

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GUANOSINE; MICRORNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG MECHANISM; GENE EXPRESSION REGULATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA REPLICATION; VIRUS ENTRY; VIRUS INHIBITION;

ANTIVIRAL AGENTS; CELL LINE; DOWN-REGULATION; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; MYCOPHENOLIC ACID; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84864410040     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.06.009     Document Type: Article

References (48)

1. Allison A.C., Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47(2-3):85-118.
2. Bahra M., Neumann U.I., Jacob D., Puhl G., Klupp J., Langrehr J.M., Berg T., Neuhaus P. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. American Journal of Transplantation 2005, 5(2):406-411.
3. Bertaux C., Dragic T. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. Journal of Virology 2006, 80(10):4940-4948.
4. Bullingham R., Monroe S., Nicholls A., Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. Journal of Clinical Pharmacology 1996, 36(4):315-324.
5. Chan T.M., Li F.K., Tang C.S., Wong R.W., Fang G.X., Ji Y.L., Lau C.S., Wong A.K., Tong M.K., Chan K.W., Lai K.N. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. New England Journal of Medicine 2000, 343(16):1156-1162.
6. Chinnadurai R., Velazquez V., Grakoui A. Hepatic transplant and HCV: a new playground for an old virus. American Journal of Transplantation 2011, 12(2):298-305.
7. Ciesek S., Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. Journal of Viral Hepatitis 2011, 19(1):1-8.
8. Diamond M.S., Zachariah M., Harris E. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 2002, 304(2):211-221.
9. Fasola C.G., Netto G.J., Jennings L.W., Christensen L.L., Molmenti E.P., Sanchez E.Q., Levy M.F., Goldstein R.M., Klintmalm G.B. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplantation Proceedings 2002, 34(5):1563-1564.
10. Firpi R.J., Nelson D.R., Davis G.L. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transplantation 2003, 9(1):57-61.
11. Gong Z.J., De Meyer S., Clarysse C., Verslype C., Neyts J., De Clercq E., Yap S.H. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. Journal of Viral Hepatitis 1999, 6(3):229-236.
12. Gurusamy K.S., Osmani B., Xirouchakis E., Burroughs A.K., Davidson B.R. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database of Systematic Reviews 2009, (1). CD006803.
13. Harrus D., Ahmed-El-Sayed N., Simister P.C., Miller S., Triconnet M., Hagedorn C.H., Mahias K., Rey F.A., Astier-Gin T., Bressanelli S. Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis. Journal of Biological Chemistry 2010, 285(43):32906-32918.
14. Henry S.D., Metselaar H.J., Lonsdale R.C., Kok A., Haagmans B.L., Tilanus H.W., van der Laan L.J. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006, 131(5):1452-1462.
15. Hossain M.M., Coull J.J., Drusano G.L., Margolis D.M. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Research 2002, 55(1):41-52.
16. Inoue K., Yoshiba M. Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. Transplantation Proceedings 2005, 37(2):1233-1234.
17. Jain A., Kashyap R., Demetris A.J., Eghstesad B., Pokharna R., Fung J.J. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transplantation 2002, 8(1):40-46.
18. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309(5740):1577-1581.
19. Khan M., Dhanwani R., Patro I.K., Rao P.V., Parida M.M. Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Research 2011, 89(1):1-8.
20. Kolykhalov A.A., Agapov E.V., Blight K.J., Mihalik K., Feinstone S.M., Rice C.M. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997, 277(5325):570-574.
21. Kornberg A., Kupper B., Tannapfel A., Hommann M., Scheele J. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. International Immunopharmacology 2005, 5(1):107-115.
22. Langford C.A., Talar-Williams C., Sneller M.C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis and Rheumatism 2004, 51(2):278-283.
23. Limaye A.R., Firpi R.J. Management of recurrent hepatitis C infection after liver transplantation. Clinics in Liver Disease 2011, 15(4):845-858.
24. Liu J.P., Ye L., Wang X., Li J.L., Ho W.Z. Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes. Transplant Infectious Disease 2011, 13(1):24-32.
25. Manrique A., Jimenez C., Ortega P., Abradelo M., Gimeno A., Calvo J., Cambra F., Sterup R.L., Morales J.M., Moreno E. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis. Transplantation Proceedings 2008, 40(9):2962-2964.
26. Marubashi S., Dono K., Nagano H., Kim C., Asaoka T., Hama N., Kobayashi S., Takeda Y., Umeshita K., Monden M., Doki Y., Mori M. Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence. Clinical Transplantation 2009, 23(6):904-913.
27. McCashland T.M. Management of liver transplant recipients with recurrent hepatitis C. Current Opinion in Organ Transplantation 2009, 14(3):221-224.
28. Mitsui A., Suzuki S. Immunosuppressive effect of mycophenolic acid. Journal of Antibiotics 1969, 22(8):358-363.
29. Nakagawa M., Sakamoto N., Tanabe Y., Koyama T., Itsui Y., Takeda Y., Chen C.H., Kakinuma S., Oooka S., Maekawa S., Enomoto N., Watanabe M. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005, 129(3):1031-1041.
30. Ong J.P., Barnes D.S., Younossi Z.M., Gramlich T., Yen-Lieberman B., Goormastic M., Sheffield C., Hoercher K., Starling R., Young J., Smedira N., McCarthy P. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999, 30(5):1293-1298.
31. Pan Q., de Ruiter P.E., Metselaar H.J., Kwekkeboom J., de Jonge J., Tilanus H.W., Janssen H.L., van der Laan L.J. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology 2012, 55:1673-1683.
32. Patel C.G., Akhlaghi F. High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma. Therapeutic Drug Monitoring 2006, 28(1):116-122.
33. Pedersen I.M., Cheng G., Wieland S., Volinia S., Croce C.M., Chisari F.V., David M. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449(7164):919-922.
34. Pillai A.A., Levitsky J. Overview of immunosuppression in liver transplantation. World Journal of Gastroenterology 2009, 15(34):4225-4233.
35. Platz K.P., Mueller A.R., Willimski C., Mansoorian B., Berg T., Neuhaus R., Hopf U., Lobeck H., Neuhaus P. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. Transplantation Proceedings 1998, 30(4):1468-1469.
36. Rakela J., Vargas H.E. Hepatitis C: magnitude of the problem. Liver Transplantation 2002, 8(10 Suppl. 1):S3-S6.
37. Ramos-Casals M., Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 2005, 14(Suppl 1):s64-s72.
38. Rostaing L., Izopet J., Sandres K., Cisterne J.M., Puel J., Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000, 69(5):991-994.
39. Schoggins J.W., Rice C.M. Interferon-stimulated genes and their antiviral effector functions. Current Opinion in Virology 2011, 1:519-525.
40. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
41. Sebastian L., Madhusudana S.N., Ravi V., Desai A. Mycophenolic acid inhibits replication of Japanese encephalitis virus. Chemotherapy 2011, 57(1):56-61.
42. Spencer C.M., Goa K.L., Gillis J.C. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997, 54(6):925-975.
43. Takhampunya R., Ubol S., Houng H.S., Cameron C.E., Padmanabhan R. Inhibition of dengue virus replication by mycophenolic acid and ribavirin. Journal of General Virology 2006, 87(Pt 7):1947-1952.
44. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine 2005, 11(7):791-796.
45. Ye L., Wang X., Wang S., Wang Y., Song L., Hou W., Zhou L., Li H., Ho W. CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes. Hepatology 2009, 49(3):753-762.
46. Zekry A., Gleeson M., Guney S., McCaughan G.W. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transplantation 2004, 10(1):52-57.
47. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., Chisari F.V. Robust hepatitis C virus infection in vitro. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(26):9294-9299.
48. Zhong W., Uss A.S., Ferrari E., Lau J.Y., Hong Z. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. Journal of Virology 2000, 74(4):2017-2022.